Evaluation of the Carba NP Test in Oregon, 2013 | Zendy

Karim Morey | Zendy; Robert Vega | Zendy; P. Maureen Cassidy | Zendy; Genevieve L. Buser | Zendy; Jaipreet Rayar | Zendy; Jeffrey A. Myers | Zendy; Scott J. Weissman | Zendy; Zintars G. Beldavs | Zendy; Christopher D. Pfeiffer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of the Carba NP Test in Oregon, 2013

Author(s) -

Karim Morey,

Robert Vega,

P. Maureen Cassidy,

Genevieve L. Buser,

Jaipreet Rayar,

Jeffrey A. Myers,

Scott J. Weissman,

Zintars G. Beldavs,

Christopher D. Pfeiffer

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.03005-15

Subject(s) - enterobacteriaceae , enterobacteriaceae infections , confidence interval , biology , carbapenem , carbapenem resistant enterobacteriaceae , microbiology and biotechnology , bacterial protein , medicine , gene , antibiotics , escherichia coli , genetics

Carbapenem-resistantEnterobacteriaceae (CRE) are an urgent public health threat. We evaluated the capacity of the Carba NP test to detect carbapenemase production in 206 isolates: 143Enterobacteriaceae identified by Oregon's CRE surveillance program in 2013 and 63 known carbapenemase-positive organisms. Overall, test sensitivity and specificity were 89% (59/66 isolates; 95% confidence interval [CI], 81 to 97%) and 100% (140/140 isolates; 95% CI, 98 to 100%), respectively. All KPC, NDM-1, VIM, and IMP producers but no (0/7 isolates) OXA-48-like strains were Carba NP positive prior to apost hoc protocol modification. We subsequently incorporated Carba NP into Oregon's CRE screening algorithm.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research